NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
Clinical Trials
6 trialsNCT04466137 2022-02-09
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01611051 2013-01-08
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01560195 2012-11-06
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown